BioSpace News Archive

Hansa Biopharma AB, “Hansa”, pioneer in enzyme technology for rare immunological conditions, announces that the first patient has been treated in the PAES for Idefirix® as a desensitization treatment for highly sensitized people undergoing a kidney transplant.

Shimadzu Medical Systems USA, a subsidiary of Shimadzu Corporation, is proud to announce the release of the MobileDaRt Evolution MX8 Version V type.

Immuron Limited is pleased to announce the FY22 sales results of its over-the-counter gastrointestinal and digestive health immune supplement Travelan® and Protectyn®.

Genentech, a member of the Roche Group, announced results from the primary analysis of the Phase III HAVEN 6 study, which show that Hemlibra® continued to demonstrate a favorable safety profile and effective bleed control in people with moderate or mild hemophilia A, without factor VIII inhibitors.

Iroquois Capital Management, LLC (together with its affiliates, “Iroquois”), announced that on Friday, July 8, 2022 , that it had delivered a written consent to PharmaCyte Biotech, Inc. (“PharmaCyte”, “PMCB” or the “Company”) (NASDAQ: PMCB) seeking the consent of stockholders to expand the size of PharmaCyte’s Board of Directors.

Axonics, Inc., a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, will report second quarter 2022 financial results after the close of trading on Monday, August 1.

NanoString Technologies, Inc., a leading provider of life science tools for discovery and translational research, announced that the Company will report second quarter 2022 operating results after the close of the market on Thursday, August 4, 2022.

Henry Schein, Inc., the world’s largest provider of health care solutions to office-based dental and medical practitioners, announced that it will release its second-quarter 2022 financial results before the stock market opens on Tuesday, August 2, 2022, and will provide a live webcast of its earnings conference call on the same day beginning at 10:00 a.m. Eastern time.

Takeda Pharmaceutical Company Limited announced that it has filed its Corporate Governance Report with the Tokyo Stock Exchange in accordance with the regulations* for TSE listed companies.

Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced the appointment of Steven W. Ryder, M.D. to its Board of Directors, effective July 11, 2022.